Nitazoxanide impairs mitophagy flux through ROS-mediated mitophagy initiation and lysosomal dysfunction in bladder cancer

Bladder Cancer is one of the most common malignancy in the urinary tract with high recurrence and drug resistance in clinics. Alternative treatments from existing drugs might be a promising strategy. Nitazoxanide (NTZ), an FDA-approved antiprotozoal drug, has got increasingly noticed because of its favorable safety profile and antitumor potential, yet the effects in bladder Cancer and underlying mechanisms remain poorly understood. Herein, we find that NTZ induces mitochondrial damage and Mitophagy initiation through PINK1-generated phospho-ubiquitin(pS65-Ub) and Autophagy receptor-mediated pathway even in the absence of Atg5/Beclin1. Meanwhile, NTZ inhibits lysosomal degradation activity, leading to Mitophagy flux impairment at late stage. Mitochondrial Reactive Oxygen Species (ROS) production is critical in this process, as eliminating ROS with N-acetylcysteine (NAC) efficiently inhibits PINK1 signaling-mediated Mitophagy initiation and alleviates lysosomal dysfunction. Co-treatment with NTZ and Autophagy Inhibitor Chloroquine (CQ) to aggravate Mitophagy flux impairment promotes NTZ-induced Apoptosis, while alleviation of Mitophagy flux impairment with ROS scavenger reduces cell death. Moreover, we also discover a similar signaling response in the 3D bladder tumor spheroid after NTZ exposure. In vivo study reveals a significant inhibition of orthotopic bladder tumors with no obvious systemic toxicity. Together, our results uncover the anti-tumor activities of NTZ with the involvement of ROS-mediated Mitophagy modulation at different stages and demonstrate it as a potential drug candidate for fighting against bladder tumors.